Month: February 2021

MONTRÉAL, 17 févr. 2021 (GLOBE NEWSWIRE) — Ressources Falco Ltée (« Falco » ou la « Société ») (TSX.V: FPC) est heureuse d’annoncer qu’elle participera prochainement à deux conférences.CONFÉRENCE MONDIALE ANNUELLE SUR LE SECTEUR DES MINES ET DES MÉTAUX DE BMOÉdition virtuelle1-5 mars 2021La conférence mondiale annuelle sur le secteur des mines et des métaux de BMO est l’un des événements les plus importants du secteur. Cette conférence virtuelle de cinq jours, sur invitation seulement, réunit des leaders de l’industrie minière et des investisseurs institutionnels du monde entier.Luc Lessard, Président et chef de la direction de Falco, fera une présentation à la conférence le jeudi 4 mars à 11h45 et sera disponible pour des rencontres individuelles tout au long de la conférence. Les demandes de réunion peuvent être...

WARREN, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results for the fourth quarter and year ended December 31, 2020 and provide a business update after market close on Tuesday, March 9, 2021.Management will host a conference call for investors at 8:00 a.m. ET on Wednesday, March 10, 2021. The conference call can be accessed by dialing (866) 417-5886 from the U.S. and (409) 217-8235 internationally, followed by the conference ID: 7828506.There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations....

Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing lossSupportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection programSAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 44th Annual MidWinter Meeting, to be held virtually February 20-24, 2021. These include participation in an invited symposium, presentation of the previously disclosed positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss, and multiple presentations related to Otonomy’s preclinical programs.“We are pleased to have the opportunity...

GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID, a novel, single-dose, intranasal COVID-19 vaccine candidate. Altimmune expects to commence patient enrollment in the Phase 1 clinical trial in the coming week.“We believe deployment of intranasal vaccines like AdCOVID will be essential to a successful global response to the pandemic,” said Vipin K. Garg, President and Chief Executive Officer of Altimmune. “FDA clearance of the IND marks an important step in developing a safe and effective vaccine designed to stimulate mucosal as well as systemic immunity following intranasal administration....

AB “Ignitis grupė” received the Letter of Expectations revised by the Ministry of FinanceAB “Ignitis grupė” (hereinafter – ‘Ignitis Group’ or ‘Company’) informs that on 17 February 2021  it received the Letter of Expectations (hereinafter – Letter) revised by the Ministry of Finance of the Republic of Lithuania (hereinafter – Ministry of Finance), which owns 73.08% of the Company’s shares.A need to revise the Letter arose after the change in the Government. The Company sees this action as positive because the Letter, in essence, approves the Company’s strategy. The expectations of the principal shareholder on the Company’s strategic directions remain consistent with the previous letters of expectations.Summary of the main changes in the Letter:Business continuity and consistency is expectedLong-term goals set for the Company must align...

AB “Ignitis grupė” (hereinafter – ‘Ignitis Group’ or ‘Company’) informs that on 17 February 2021  it received the Letter of Expectations (hereinafter – Letter) revised by the Ministry of Finance of the Republic of Lithuania (hereinafter – Ministry of Finance), which owns 73.08% of the Company’s shares.A need to revise the Letter arose after the change in the Government. The Company sees this action as positive because the Letter, in essence, approves the Company’s strategy. The expectations of the principal shareholder on the Company’s strategic directions remain consistent with the previous letters of expectations.Summary of the main changes in the Letter:Business continuity and consistency is expectedLong-term goals set for the Company must align with the four-year strategic plan. The long-term goals set for key executives must align...

AB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė) informuoja, kad 2021 m. vasario 17 d. gavo 73,08 proc. Bendrovės akcijų valdančios Lietuvos Respublikos finansų ministerijos (toliau – Finansų ministerija)  papildytą akcininko lūkesčių raštą (toliau – Lūkesčių raštas).Lūkesčių rašto peržiūros poreikis atsirado pasikeitus Vyriausybei. Bendrovė šį žingsnį vertina teigiamai, nes Lūkesčių raštu pritariama Bendrovės vykdomai strategijai. Pagrindinio akcininko keliami lūkesčiai strateginėms Bendrovės kryptims yra nepakitę ir nuoseklūs ankstesniems lūkesčių raštams.Pagrindiniai pokyčiai Lūkesčių rašte trumpai:Tikimasi tolimesnio veiklos tęstinumo ir nuoseklumo;Bendrovei keliami ilgalaikiai tikslai turi būti susieti su ketverių metų strateginiu planu. O pagrindiniams vadovams keliami ilgalaikiai tikslai turi atitikti Bendrovės ilgalaikius...

MONTRÉAL, Feb. 17, 2021 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) today announced that it has initiated the repayment of the total outstanding balance of $750 million drawn on its $1 billion senior secured term loan facility (the “Facility”) established on August 19, 2020. Payout of the Facility, including all accrued interest and associated fees, will be completed on February 19, 2021.About BombardierBombardier is a global leader in aviation, creating innovative and game-changing planes. Our products and services provide world-class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.Headquartered in Montréal, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide...

MONTRÉAL, 17 févr. 2021 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) a annoncé aujourd’hui qu’elle a commencé le remboursement du solde total prélevé de 750 millions $ sur la facilité de prêt à terme garantie de premier rang d’un montant de 1,0 milliard $ (la « Facilité »), mise en place le 19 août 2020. Le remboursement de la Facilité, y compris celui de tous les intérêts courus et frais associés, s’achèvera le 19 février 2021.À propos de BombardierBombardier est un leader mondial de l’industrie de l’aviation en créant des avions novateurs qui changent la donne sur leur marché. Ses produits et services fournissent des expériences de calibre international établissant de nouvelles normes en matière de confort-passager, d’efficacité écoénergétique, de fiabilité et de sécurité.Ayant son siège social à Montréal, au Canada, Bombardier...